IOL Chemicals and Pharmaceuticals 과거 수익 실적
과거 기준 확인 1/6
IOL Chemicals and Pharmaceuticals의 수입은 연평균 -29%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 13.4%의 비율로 증가했습니다. 매출은 연평균 3.3%의 비율로 증가해 왔습니다. IOL Chemicals and Pharmaceuticals의 자기자본이익률은 6%이고 순이익률은 4.9%입니다.
주요 정보
-29.0%
수익 성장률
-29.7%
EPS 성장률
| Pharmaceuticals 산업 성장 | 17.5% |
| 매출 성장률 | 3.3% |
| 자기자본 수익률 | 6.0% |
| 순이익 | 4.9% |
| 다음 실적 업데이트 | 19 Nov 2024 |
최근 과거 실적 업데이트
Recent updates
A Piece Of The Puzzle Missing From IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Share Price
Sep 11
Is There An Opportunity With IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) 34% Undervaluation?
Jun 12Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?
Aug 30IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Has A Pretty Healthy Balance Sheet
May 18IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Will Pay A Dividend Of ₹4.00
Feb 10Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?
Jun 07Calculating The Intrinsic Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)
May 07Do IOL Chemicals and Pharmaceuticals's (NSE:IOLCP) Earnings Warrant Your Attention?
May 04Is IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP) An Attractive Dividend Stock?
Mar 13Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?
Feb 23Should You Rely On IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) Earnings Growth?
Feb 08IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Jan 27How Does IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) CEO Salary Compare to Peers?
Jan 15Estimating The Intrinsic Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)
Jan 02
Shareholders of IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Must Be Delighted With Their 869% Total Return
Dec 21Is Now The Time To Put IOL Chemicals and Pharmaceuticals (NSE:IOLCP) On Your Watchlist?
Dec 09These 4 Measures Indicate That IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Is Using Debt Reasonably Well
Nov 24IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Could Be A Buy For Its Upcoming Dividend
Nov 12Is There More To The Story Than IOL Chemicals and Pharmaceuticals's (NSE:IOLCP) Earnings Growth?
Nov 09Will Weakness in IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Stock Prove Temporary Given Strong Fundamentals?
Oct 27Here's What We Think About IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) CEO Pay
Oct 09Calculating The Fair Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)
Sep 18Here's Why I Think IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Might Deserve Your Attention Today
Sep 03Cautious Investors Not Rewarding IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Performance Completely
Aug 16IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Seems To Use Debt Rather Sparingly
Jul 27수익 및 비용 분석
수익 및 비용 분석
IOL Chemicals and Pharmaceuticals 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 30 Sep 24 | 20,521 | 998 | 2,114 | 0 |
| 30 Jun 24 | 20,720 | 1,185 | 2,017 | 0 |
| 31 Mar 24 | 21,328 | 1,344 | 2,027 | 0 |
| 31 Dec 23 | 22,161 | 1,716 | 1,938 | 0 |
| 30 Sep 23 | 22,192 | 1,723 | 1,873 | 0 |
| 30 Jun 23 | 22,153 | 1,503 | 1,787 | 0 |
| 31 Mar 23 | 22,171 | 1,391 | 1,686 | 0 |
| 31 Dec 22 | 22,024 | 1,041 | 1,633 | 0 |
| 30 Sep 22 | 22,341 | 1,204 | 1,567 | 0 |
| 30 Jun 22 | 22,305 | 1,353 | 1,518 | 0 |
| 31 Mar 22 | 21,840 | 1,677 | 1,415 | 0 |
| 31 Dec 21 | 20,719 | 2,132 | 1,350 | 0 |
| 30 Sep 21 | 20,298 | 2,879 | 1,280 | 0 |
| 30 Jun 21 | 20,254 | 3,840 | 1,251 | 0 |
| 31 Mar 21 | 19,670 | 4,446 | 1,157 | 0 |
| 31 Dec 20 | 19,481 | 4,596 | 1,104 | 0 |
| 30 Sep 20 | 19,463 | 4,428 | 1,062 | 0 |
| 30 Jun 20 | 18,618 | 4,035 | 975 | 0 |
| 31 Mar 20 | 18,945 | 3,613 | 974 | 0 |
| 31 Dec 19 | 18,753 | 3,727 | 923 | 0 |
| 30 Sep 19 | 18,423 | 3,569 | 904 | 0 |
| 30 Jun 19 | 18,163 | 3,076 | 855 | 0 |
| 31 Mar 19 | 16,853 | 2,367 | 794 | 0 |
| 31 Dec 18 | 15,506 | 1,465 | 736 | 0 |
| 30 Sep 18 | 13,350 | 731 | 657 | 0 |
| 30 Jun 18 | 11,298 | 391 | 605 | 0 |
| 31 Mar 18 | 9,833 | 277 | 562 | 0 |
| 31 Dec 17 | 8,891 | 178 | 526 | 0 |
| 30 Sep 17 | 8,094 | 100 | 495 | 0 |
| 30 Jun 17 | 8,265 | 65 | 26 | 0 |
| 31 Mar 17 | 7,107 | 47 | 433 | 0 |
| 31 Dec 16 | 6,595 | 39 | 436 | 0 |
| 30 Sep 16 | 6,197 | -74 | 407 | 0 |
| 30 Jun 16 | 6,055 | -214 | 382 | 0 |
| 31 Mar 16 | 5,804 | -400 | 352 | 0 |
| 31 Dec 15 | 5,131 | -692 | 386 | 0 |
| 30 Sep 15 | 4,377 | -890 | 363 | 0 |
| 30 Jun 15 | 4,008 | -858 | 261 | 0 |
| 31 Mar 15 | 3,847 | -667 | 248 | 0 |
| 31 Dec 14 | 4,405 | -378 | 277 | 0 |
| 30 Sep 14 | 5,115 | -71 | 281 | 0 |
| 30 Jun 14 | 5,452 | 37 | 271 | 0 |
| 31 Mar 14 | 5,635 | 33 | 398 | 0 |
| 31 Dec 13 | 5,684 | 26 | 267 | 0 |
양질의 수익: IOLCP 은 높은 수익을 보유하고 있습니다.
이익 마진 증가: IOLCP 의 현재 순이익 이익률 (4.9%) 작년보다 낮습니다 (7.8%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: IOLCP 의 수입은 지난 5년 동안 매년 29% 씩 감소했습니다.
성장 가속화: IOLCP 은(는) 지난 1년 동안 마이너스 수익 성장을 기록했기 때문에 5년 평균과 비교할 수 없습니다.
수익 대 산업: IOLCP 은 지난 1년 동안 마이너스 수익 성장( -42.1% )을 기록하여 Pharmaceuticals 업계 평균( 19.2% ).
자기자본 수익률
높은 ROE: IOLCP 의 자본 수익률( 6% )은 낮음으로 간주됩니다.